Literature DB >> 8324731

The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma.

M S Sheikh1, Z M Shao, A Hussain, J A Fontana.   

Abstract

The human p53-binding protein murine double minute 2 (MDM2) is believed to function as a negative regulator of p53. The MDM2 gene was cloned and sequenced only recently and was found to be amplified in a variety of sarcomas. Although mutations in the p53 gene have been shown to occur in human breast carcinoma (HBC), no information is available on MDM2 gene expression in HBC. In this study we report for the first time that the MDM2 gene is differentially expressed in HBC. Our results demonstrate a correlation between the estrogen receptor (ER) status and the MDM2 mRNA levels. In contrast to the ER-negative cell lines, all the ER-positive cell lines were found to express higher levels of MDM2 mRNA. ER-positive ZR-75 cells express 30-fold higher levels of MDM2 mRNA than does the ER-negative cell line Hs578T. Estrogen enhanced albeit modestly the MDM2 mRNA levels in ER-positive MCF-7 cells. Estrogen enhancement of MDM2 mRNA levels was also observed in ER-negative MDA-MB-231 cells transfected with functional ERs. Our data thus suggest that estrogen may play an important role in HBC growth stimulation by modulating the expression of MDM2, which in turn may inactivate the p53 function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324731

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

Review 1.  Cell cycle checkpoints as therapeutic targets.

Authors:  Z A Stewart; J A Pietenpol
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

2.  Low Grade Amplification of MDM2 Gene in a Subset of Human Breast Cancers without p53 Alterations.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

3.  A genetic approach to mapping the p53 binding site in the MDM2 protein.

Authors:  D A Freedman; C B Epstein; J C Roth; A J Levine
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

Review 4.  Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk.

Authors:  Stian Knappskog; Per E Lønning
Journal:  Transcription       Date:  2011 Sep-Oct

5.  The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2.

Authors:  S N Jones; A T Sands; A R Hancock; H Vogel; L A Donehower; S P Linke; G M Wahl; A Bradley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

6.  The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis.

Authors:  D R Brown; C A Thomas; S P Deb
Journal:  EMBO J       Date:  1998-05-01       Impact factor: 11.598

7.  Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis.

Authors:  Michael I Carr; Stephen N Jones
Journal:  Transl Cancer Res       Date:  2016-12       Impact factor: 1.241

8.  Progesterone inhibition of MDM2 p90 protein in MCF-7 human breast cancer cell line is dependent on p53 levels.

Authors:  Moussa Alkhalaf; Abdalla M El-Mowafy; Laila A Abou-Zeid
Journal:  J Mol Genet Med       Date:  2005-08-19

9.  Knockdown of Gli1 by small-interfering RNA enhances the effects of BCNU on the proliferation and apoptosis of glioma U251 cells.

Authors:  Wenjia Guo; Hailong Tian; Xiaogang Dong; Jinping Bai; Xinling Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

10.  Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature.

Authors:  Andrea Köhrmann; Ulrike Kammerer; Michaela Kapp; Johannes Dietl; Jelena Anacker
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.